Sacituzumab govitecan, a novel investigational antibody-drug conjugate, showed clinical activity in patients with metastatic urothelial carcinoma (mUC) who had progressed following standard therapy, including treatment with checkpoint inhibitors, according to an early study presented at GUCS 2019.
Patients with urologic cancers are more likely to attempt suicide, highlighting the need for increased psychiatric intervention for these patients at an earlier stage, according to findings presented at the European Association of Urology (EAU) 2018 Congress.
Women who undergo radical cystectomy for bladder cancer are more likely to have worse outcomes, including disease-free survival, cancer-specific survival and overall survival, compared with their male counterparts, a study reports.
Office-based blue light flexible cystoscopy significantly improves detection of patients with recurrent bladder cancer and is safe when performed for surveillance compared white light flexible cystoscopy, as shown in a recent study.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
Optimizing perioperative chemotherapy in bladder cancer (BC) presents a clinical challenge, as reflected in a debate at the 15th Urological Association of Asia Congress held in Hong Kong, which focused on the benefits and drawbacks of adjuvant chemotherapy (AC) after radical cystectomy (RC).
Extended-duration enoxaparin appears to be more effective than inpatient-only subcutaneous heparin in the prevention of venous thromboembolism (VTE) following radical cystectomy, reducing the rate of thromboembolic events without increasing the risk of bleeding, according to a study.
Neoadjuvant chemotherapy (NCT) is effective and should be standard care for muscle-invasive bladder cancer (MIBC), according to a recent study. Furthermore, methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) appeared to have superior overall survival compared with gemcitabine and cisplatin/carboplatin (GC) in the neoadjuvant setting.
A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.